The estimated Net Worth of Jean I Liu is at least $32.9 Milione dollars as of 21 September 2023. Ms. Liu owns over 64 units of Seagen Inc stock worth over $19,315,326 and over the last 21 years she sold SGEN stock worth over $9,627,587. In addition, she makes $3,966,120 as Executive Vice President - Legal Affairs, General Counsel e Corporate Secretary at Seagen Inc.
Jean has made over 37 trades of the Seagen Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently she sold 64 units of SGEN stock worth $13,216 on 21 September 2023.
The largest trade she's ever made was exercising 34,876 units of Seagen Inc stock on 1 November 2021 worth over $1,253,792. On average, Jean trades about 2,662 units every 54 days since 2004. As of 21 September 2023 she still owns at least 84,398 units of Seagen Inc stock.
You can see the complete history of Ms. Liu stock trades at the bottom of the page.
Jean I. Liu J.D. serves as Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary of the Company. Prior to that, she served as Vice President and General Counsel of Halozyme Therapeutics, Inc., a publicly-traded biotechnology company, from November 2011 to November 2014. From 1998 to 2011, she was with Durect Corporation, a publicly-traded biotechnology company, where she served in positions of increasing responsibility, including most recently Chief Legal Officer and Corporate Secretary. Prior to Durect, Ms. Liu was with the law firms of Pillsbury, Madison & Sutro (now Pillsbury Winthrop) and Venture Law Group where she focused on broad areas of legal advisory for early stage companies, including technology transfer, licensing, patents, and copyright and trademark litigation. Ms. Liu received her B.S. in Cellular and Molecular Biology with highest distinction from the University of Michigan, her M.S. in Biology from Stanford University and her J.D. from Columbia University where she was a Harlan Fiske Stone Scholar.
As the Executive Vice President - Legal Affairs, General Counsel e Corporate Secretary of Seagen Inc, the total compensation of Jean Liu at Seagen Inc is $3,966,120. There are 3 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.
Jean Liu is 51, she's been the Executive Vice President - Legal Affairs, General Counsel e Corporate Secretary of Seagen Inc since 2014. There are 18 older and 1 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro... e Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: